← All companies
$295.03
+0.20% (+$0.58) on the day
Close Nov 13, 2026
Market cap
$522B
1 month
+4.10%
52-week range
$190.75–$302.93
Last month
Why we cover it
Bought bretisilocin, a short-acting psychedelic for depression, outright from Gilgamesh Pharmaceuticals for up to $1.2 billion in 2025, one of the first big pharma deals in the field.
Financials
| Cash & equivalents | $10.8B | as of Sep 30, 2026 · 10-Q |
| Revenue | $17.4B | quarter ended Sep 30, 2026 · 10-Q |
| Research & development | $2.57B | quarter ended Sep 30, 2026 · 10-Q |
| Net income (loss) | $4.22B | quarter ended Sep 30, 2026 · 10-Q |
From the company's SEC filings. See all filings ↗
In the Journal (4)
- Sep 21, 2026 19% of American Adults Have Anxiety. Every Drug Treating It Is a Decades-Old Generic — Here's Who Wins If DT120 Changes That
- Sep 17, 2026 The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
- Aug 28, 2026 Altitude Intelligence Brief: Who's Actually Making Money on Depression, Anxiety, and PTSD
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.